Psoriatic Arthritis

Results show that bimekizumab achieved significantly higher ACR50 response rates at week 16 than risankizumab in adults with active PsA.

Patients treated with deucravacitinib achieved higher ACR20 response rates at week 16 than those receiving placebo in the POETYK PsA studies.

Results from the TOGETHER-PsA trial reveal that combining ixekizumab and tirzepatide significantly improves outcomes for patients with psoriatic arthritis (PsA) and obesity.

New long-term findings reveal guselkumab (TREMFYA) as the only IL-23 inhibitor effectively preventing joint damage in active psoriatic arthritis.

Bristol Myers Squibb reveals promising data on deucravacitinib's efficacy for psoriatic arthritis and systemic lupus erythematosus, highlighting its potential as a new treatment option.

Phase 3 PROTOSTAR data support new indications, expanding treatment options for children impacted by chronic immune-mediated diseases.

By blocking 2 key inflammation signals, research presented at EADV found bimekizumab may help keep both skin and joints healthier over time.

Deucravacitinib-treated patients achieved superior clinical responses compared to placebo at week 16 in both trials.

Johnson & Johnson seeks FDA approval to update guselkumab's label, highlighting its unique ability to significantly inhibit joint damage in active psoriatic arthritis.

Sun Pharma reveals promising phase 3 results for tildrakizumab (Ilumya) in treating PsA, showing significant symptom improvement in patients.

Bristol Myers Squibb's deucravacitinib gains global regulatory acceptance for treating active psoriatic arthritis, promising a new oral treatment option.

Apremilast improved joint symptoms and quality of life in patients with early oligoarticular PsA, with consistent efficacy across all BMI categories.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Data presented at EULAR 2025 showcased Tremfya's efficacy as the only IL-23 inhibitor to demonstrate inhibition of this nature in psoriatic arthritis.

At the 2025 EULAR meeting, UCB presented new 3-year data on bimekizumab for PsA.

The National Psoriasis Foundation Seal of Recognition program has expanded to prescription drugs, making roflumilast the first to achieve the indication.

Tremfya is the first IL-23 inhibitor to significantly improve both symptoms and structural damage in active psoriatic arthritis.

Unlike biologics, nonbiologic systemic therapies showed a neutral or slightly increased cardiovascular risk, raising concerns about their long-term safety.

A study reveals that biologics targeting IL-12, IL-23, and IL-17 lower the risk of serious infections in older adults with psoriatic disease.

According to a poster from AAD, the National Psoriasis Foundation’s treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.

Ustekinumab-kfce is available for the treatment of chronic autoimmune conditions like Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Advances in biologics, JAK inhibitors, and PDE4 inhibitors provide personalized options for psoriasis management.

Researchers found that PsA patients prioritize fatigue, sleep issues, and uncertainty, often ranking them higher than doctors do.

Effective PsA management requires balancing clinical goals with patient-reported challenges like fatigue and daily disruptions.

Deucravacitinib achieved ACR20 response in patients with PsA at week 16, with a safety profile consistent with previous studies.